<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03435562</url>
  </required_header>
  <id_info>
    <org_study_id>HM20012013</org_study_id>
    <nct_id>NCT03435562</nct_id>
  </id_info>
  <brief_title>Assessment of Two New Electronic Cigarettes in Cigarette Smokers</brief_title>
  <official_title>Assessment of Two New Electronic Cigarettes in Cigarette Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine differences in nicotine delivery, user behavior,
      subjective effects, and physiological effects, when cigarette smokers use an two new
      electronic cigarette devices (JUUL and IQOS) relative to their using their own brand of
      cigarettes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 3, 2018</start_date>
  <completion_date type="Actual">August 16, 2019</completion_date>
  <primary_completion_date type="Actual">August 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma nicotine</measure>
    <time_frame>Blood will be taken 4 times in each session: at baseline, 5 min after the start of a 10-puff product use, and then before and after an approximately 1-hour ad lib use period.</time_frame>
    <description>Change in plasma nicotine level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hughes-Hatsukami Questionnaire</measure>
    <time_frame>Questionnaire will be administered 4 times in each approximately 4-hr session: before any product use, 10 minutes after the start of a 10-puff use bout, and then before and after an approximately 1-hour ad lib use period.</time_frame>
    <description>This scale is used to assess the extent to which product use reduces tobacco abstinence symptoms, and consists of 11 items scored 0 - 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tiffany-Drobes Questionnaire of Smoking Urges</measure>
    <time_frame>Questionnaire will be administered 4 times in each each approximately 4-hr session: before any product use, 10 minutes after the start of a 10-puff use bout, and then before and after an approximately 1-hour ad lib use period.</time_frame>
    <description>This scale is used to assess the extent to which product use reduces tobacco abstinence symptoms, and consists of 10 items that are scored 0 - 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct Effects of Product Use Questionnaire</measure>
    <time_frame>Questionnaire will be administered 2 times in each each approximately 4-hr session: 10 minutes after the start of a 10-puff use bout, and then after an approxiamtely 1-hour ad lib use period.</time_frame>
    <description>This scale is used to assess how product use makes participants feel and consists of 10 questions that are scored 0 - 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct Effects of Nicotine Questionnaire</measure>
    <time_frame>Questionnaire will be administered 4 times in each each approximately 4-hr session: before any product use, 10 minutes after the start of a 10-puff use bout, and then before and after an approximately 1-hour ad lib use period.</time_frame>
    <description>This scale is used to assess how product use makes participants feel, and consists of 10 questions that are scored 0 - 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carbon monoxide levels</measure>
    <time_frame>Carbon monoxide levels will be assessed before and after product use in each approximately 4-hr session: at baseline, 5 min after the end of a 10-puff product use, and then before and after an approximately 1-hour ad lib use period.</time_frame>
    <description>Change in carbon monoxide levels (in parts per mission)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>Heat rate will be measured from baseline continuously throughout each each approximately 4-hr session</time_frame>
    <description>Change in heart rate, measured in beats per minute</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Blood pressure will be measured from baseline continuously throughout each approximately 4-hr session</time_frame>
    <description>Change in blood pressure, measured in mm/hg</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Electronic Cigarettes</condition>
  <arm_group>
    <arm_group_label>JUUL electronic cigarette use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each session, participants will first complete a 10-puff product use bout with JUUL, and then a 90-minute ad lib product use bout with JUUL (each session will be approximately 3 hours).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IQOS electronic cigarette use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each session, participants will first complete a 10-puff product use bout with IQOS, and then a 90-minute ad lib product use bout with IQOS (each session will be approximately 3 hours).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Own brand cigarette use</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During each session, participants will first complete a 10-puff product use bout with their own brand cigarettes, and then a 90-minute ad lib product use bout with their own brand cigarette (each session will be approximately 3 hours).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JUUL electronic cigarette</intervention_name>
    <description>Effects of JUUL electronic cigarette use.</description>
    <arm_group_label>JUUL electronic cigarette use</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IQOS electronic cigarette</intervention_name>
    <description>Effects of IQOS electronic cigarette use.</description>
    <arm_group_label>IQOS electronic cigarette use</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Own Brand cigarette</intervention_name>
    <description>Effects of own brand cigarette use.</description>
    <arm_group_label>Own brand cigarette use</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria--participants must be:

          -  healthy (determined by self-report)

          -  between the ages of 18-55

          -  willing to provide informed consent

          -  able to attend the lab and abstain from tobacco/nicotine as required and must agree to
             use designated products according to study protocol

          -  cigarette smokers

        Exclusion Criteria:

          -  Women if they are breast-feeding or test positive for pregnancy (by urinalysis) at
             screening.

          -  Individuals who weigh less than 110 pounds

        Some study details about the eligibility criteria are purposely omitted at this time to
        preserve scientific integrity. Full details will be posted at the conclusion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Breland, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Behavioral Pharmacolgy Laboratory</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>August 16, 2019</last_update_submitted>
  <last_update_submitted_qc>August 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03435562/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>June 29, 2020</submitted>
    <returned>July 15, 2020</returned>
    <submitted>July 16, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

